PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 30, 2026Journal of Clinical Oncology0 citations

Efficacy and Safety of Third-Line Treatments in Metastatic Colorectal Cancer

Efficacy and safety of third-line treatments in metastatic colorectal cancer: A meta-analysis.

View Full Paper
Ask AI
Bookmark
Share

Authors

AEAbdullah EsmailWAWaseem AbdelrahimYHYazan Hamadneh

Discussion

Loading...

Member takes

Overview

Meta-analysis shows third-line treatments improve survival in refractory metastatic colorectal cancer, suggesting trifluridine-tipiracil plus bevacizumab as a preferred option.

Key Points

  • This research aims to evaluate the efficacy and safety of third-line treatments for metastatic colorectal cancer. The study compares various therapies against placebo.
  • Conducted a PRISMA-compliant systematic review of phase II/III trials
  • Reconstructed individual patient data from Kaplan-Meier curves
  • Analyzed pooled estimates of overall survival, progression-free survival, and adverse events.
  • Trifluridine-tipiracil plus bevacizumab improved median progression-free survival to 5.51 months (HR 0.37, p < 0.001) versus placebo.
  • Fruquintinib demonstrated superior progression-free survival compared to regorafenib (HR 0.72, p < 0.001).
  • All active treatments significantly improved overall survival compared to placebo, highlighting trifluridine-tipiracil plus bevacizumab as best.

Cite This Study

Esmail et al. (2026) studied this question.

synapsesocial.com/papers/6a1a7fef0307b78509432154https://doi.org/10.1200/jco.2026.44.16_suppl.e15623
View Full Paper
Ask AI
Bookmark
Share